Nonviral cytokine gene therapy on an orthotopic bladder cancer model

Clinical Cancer Research

Volumn 9, Issue 12, 2003, Pages 4522-4528

  Wu, Qinghui ^a   Mahendran, Ratha ^a   Esuvaranathan, Kesavan ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

5 BROMO 4 CHLORO 3 INDOLYL BETA DEXTRO GALACTOPYRANOSIDE; ALPHA1 INTERFERON; CATION; CHOLESTEROL; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; LIPID; LIPOSOME; MB 49; METHYL BETA CYCLODEXTRIN; N [1 (2,3 DIOLEOYLOXYL)PROPYL] N,N,N TRIMETHYLAMMONIUM METHYL SULFATE; PLASMID DNA; PLASMID VECTOR; PYRANOSIDE; TRIMETHYLAMMONIUM SALT DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLADDER CANCER; BLADDER TUMOR; CAUTERIZATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE MODEL; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETIC TRANSFECTION; IN VIVO STUDY; MOUSE; NONHUMAN; NONVIRAL GENE THERAPY; PLASMID; PLASMID VECTOR PBUDCE4.1; PRIORITY JOURNAL;

ADMINISTRATION, INTRAVESICAL; ANIMALS; CARCINOMA, TRANSITIONAL CELL; CELL DIVISION; CHOLESTEROL; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GENE THERAPY; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; IMMUNOENZYME TECHNIQUES; INTERFERON-ALPHA; LIPID METABOLISM; LIPOSOMES; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEOPLASMS, EXPERIMENTAL; PLASMIDS; TRANSFECTION; TUMOR CELLS, CULTURED; URINARY BLADDER NEOPLASMS;

EID: 0141960420     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Cancer facts and figures, pp. 6, Atlanta, American Cancer Society, 2003.
2. Herr, H. W., Wartinger, D. D., Fair, W. R., and Oettgen, H. F. Bacillus Calmette-Guerin therapy for superficial bladder cancer: a 10-year follow-up. J. Urol., 147: 1020-1023, 1992.
3. Lamm, D. L., Thor, D. E., Harris, S. C., Reyna, J. A., Stogdill, V. D., and Radwin, H. M. Bacillus Calmette-Guerin immunotherapy of superficial bladder cancer. J. Urol., 124: 38-40, 1980.
4. Alexandroff, A. B., Jackson, A. M., O'Donnell, M. A., and James, K. BCG immunotherapy of bladder cancer: 20 years on. Lancet, 353: 1689-1694, 1999.
5. Sternberg, C. N., Arena, M. G., Pansadoro, V., Calabresi, F., D'Agnano, I., De Carli, P., Zeuli, M., Cancrini, A., Rosenkaimer, F., and Zupi, G. Recombinant tumor necrosis factor for superficial bladder tumors. Ann. Oncol., 3: 741-745, 1992.
6. Sarosdy, M. High-dose versus low-dose intravesical interferon-α 2b in the treatment of carcinoma in situ: a randomized, controlled study. Anticancer Drugs, 1 (Suppl.): 13-17, 1992.
7. Hermann, G. G., Geertsen, P. F., Von der Maase, H., Steven, K., Andersen, C., Hald, T., and Zeuthen, J. Recombinant interleukin-2 and lymphokine-activated killer cell treatment of advanced bladder cancer: clinical results and immunological effects. Cancer Res., 52: 726-733, 1992.
8. Stravoravdi, P., Toliou, T., Kirtsis, P., Natsis, K., Konstandinidis, E., Barich, A., Gigis, P., and Dimitriadis, K. J. A new approach in the management of urothelial tumors using GM-CSF on marker lesions: an ultrastructural and immunohistochemical study on the macrophage population in bladder mucosa. Interferon Cytokine Res., 19: 221-225, 1999.
9. Colombo, M. P., Modesti, A., Parmiani, G., and Fomi, G. Local cytokine availability elicits tumor rejection and systemic immunity through granulocyte-T-lymphocyte cross-talk. Cancer Res., 52: 4853-4857, 1992.
10. Morris, B. D., Jr., Drazan, K. E., Csete, M. E., Werthman, P. E., Van Bree, M. P., Rosenthal, J. T., and Shaked, A. Adenoviral-mediated gene transfer to bladder in vivo. J. Urol., 152: 506-509, 1994.
11. Li, Y., Pong, R. C., Bergelson, J. M., Hall, M. C., Sagalowsky, A. I., Tseng, C. P., Wang, Z., and Hsieh, J. T. Loss of adenoviral receptor expression in human bladder cancer cells: a potential impact on the efficacy of gene therapy. Cancer Res., 59: 325-330, 1999.
12. Sachs, M. D., Rauen, K. A., Ramamurthy, M., Dodson, J. L., De Marzo, A. M., Putzi, M. J., Schoenberg, M. P., and Rodriguez, R. Integrin α(v) and coxsackie adenovirus receptor expression in clinical bladder cancer. Urology, 60: 531-536, 2002.
13. Loskog, A., Hedlund, T., Wester, K., De la Torre, M., Philipson, L., Malmstrom, P. U., and Totterman, T. H. Human urinary bladder carcinomas express adenovirus attachment and internalization receptors. Gene Ther., 9: 547-553, 2002.
14. Chester, J. D., Kennedy, W., Hall, G. D., Selby, P. J., and Knowles, M. A. Adenovirus-mediated gene therapy for bladder cancer: efficient gene delivery to normal and malignant human urothelial cells in vitro and ex vivo. Gene Ther., 10: 172, 2003.
15. Horiguchi, Y., Larchian, W. A., Kaplinsky, R., Fair, W. R., and Heston. W. D. Intravesical liposome-mediated interleukin-2 gene therapy in orthotopic murine bladder cancer model. Gene Ther., 7: 844-851, 2000.
16. Harimoto, K., Sugimura, K., Lee, C. R., Kuratsukuri, K., and Kishimoto, T. In vivo gene transfer methods in the bladder without viral vectors. Br. J. Urol., 81: 870-874, 1998.
17. Lawrencia, C., Mahendran, R., and Esuvaranathan, K. Transfection of urothelial cells using methyl-β-cyclodextrin solubilized cholesterol and Dotap. Gene Ther., 8: 760-768, 2001.
18. Hertzog, P. J., Hwang, S. Y., and Kola, I. Role of interferons in the regulation of cell proliferation, differentiation, and development. Mol. Reprod. Dev. 39: 226-232, 1994.
19. Slaton, J. W., Perrotte, P., Inoue, K., Dinney, C. P. N., and Fidler, I. J. Interferon α-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule. Clin. Cancer Res., 5: 2726-2734, 1995.
20. Slaton, J. W., Karashima, T., Perrotte, P., Inoue, K., Kim, S. J., Izawa, J., Kedar, D., McConkey, D. J., Millikan, R., Sweeney, P., Yoshikawa, C., Shuin, T., and Dinney, C. P. Treatment with low-dose interferon-α restores the balance between matrix metalloproteinase-9 and E-cadherin expression in human transitional cell carcinoma of the bladder. Clin. Cancer Res., 7: 2840-2853, 2001.
21. Pardoll, D. M. Paracrine cytokine adjuvants in cancer immunotherapy. Annu. Rev. Immunol., 13: 399-415, 1995.
22. Steinman, R. M. The dendritic cell system and its role in immunogenicity. Annu. Rev. Immunol., 9: 271-296, 1991.
23. Soloway, M. S., and Masters, S. Urothelial susceptibility to tumor cell implantation. Influence of cauterization. Cancer (Phila.), 46: 1158-1158, 1980.
24. Gunther, J. H., Jurczok, A., Wulf, T., Brandau, S., Deinert, I., Jocham, D., and Bohle, A. Optimizing syngeneic orthotopic murine bladder cancer (MB49). Cancer Res., 59: 2834-2837, 1999.
25. Jiang, F., and Zhou, X. M. A model of orthotopic murine bladder (MBT-2) tumor implants. Urol. Res., 25: 179-182, 1997.
26. Watanabe, T., Shinohara, N., Sazawa, A., Harabayashi, T., Ogiso, Y., Koyanagi, T., Takiguchi, M., Hashimoto, A., Kuzumaki, N., Yamashita, M., Tanaka, M., Grossman, H. B., and Benedict, W. F. An improved intravesical model using human bladder cancer cell lines to optimize gene and other therapies. Cancer Gene Ther., 7: 1575-1580, 2000.
27. Shapiro, A., Kelley, D. R., Oakley, D. M., Catalona, W. J., and Ratliff, T. L. Technical factors affecting the reproducibility of intravesical mouse bladder tumor implantation during therapy with Bacillus Calmette-Guérin. Cancer Res., 44: 3051-3054, 1984.
28. Rubben, H., Friedrichs, R., Stuhlsatz, H. W., and Lutzeyer, W. Glycosaminoglycans in urothelial carcinomas. Urol Res., 11: 163-166, 1983.
29. Ferrantini, M., Giovarelli, M., Modesti, A., Musiani, P., Modica, A., Venditti, M., Peretti, E., Lollini, P. L., Nanni, P., and Forni, G. α1-Interferon gene transfer into metastatic Friend leukemia cells abrogated tumorigenicity in immunocompetent mice: antitumor therapy by means of interferon-producing cells. Cancer Res., 53: 1107-1112, 1993.
30. Shi, F. S., Weber, S., Gan, J., Rakhmilevich, A. L., and Mahvi, D. M. Granulocyte-macrophage colony-stimulating factor (GM-CSF) secreted by cDNA-transfected tumor cells induces a more potent antitumor response than exogenous GM-CSF. Cancer Gene Ther., 6: 81-88, 1999.
31. Theano, T., Pelagia, S., Konstantinos, N., Petros, K., Alfred, B., Konstantinos, D., and Panagiotis, G. Lymphocyte activation by granulocyte macrophage-colony stimulating factor in human bladder cancer. J. Exp. Ther. Oncol., 2: 153-157, 2002.
32. Takahashi, T., Kushiro, A., Nomoto, K., Uchida, K., Morotomi, M., Yokokura, T., and Akaza, H. Antitumor effects of the intravesical instillation of heat killed cells of the Lactobacillus casei strain Shirota on the murine orthotopic bladder tumor MBT-2. J. Urol., 166: 2506-2511, 2001.